BGB B 2033
Alternative Names: BGB-B2033Latest Information Update: 14 Jun 2025
At a glance
- Originator BeiGene
- Developer BeOne Medicines
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action CD137 antigen modulators; GPC3 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 23 Jul 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in New Zealand, China and USA (IV) (NCT06427941)
- 23 Jul 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in New Zealand, China, and USA (IV) (NCT06427941)